• 대한의생명과학회지
• /
• 제25권4호
• /
• pp.417-425
• /
• 2019

Cadmium (Cd) generates reactive oxygen species (ROS), which in turn cause the apoptosis of various cell types including developing germ cells in rodent testis. Ascorbic acids (AA), one of the ROS scavengers, had been reported to protect against Cd-induced apoptosis. N-Acetyl-L-cysteine (NAC), another ROS scavenger, is known to remove ROS and alleviate the Cd-induced apoptosis in various cell types. In this study we tried to elucidate how NAC affected on Cd-induced cell apoptosis in rat testis. Rats were administered with NAC before and after Cd treatment and then testicular cell apoptosis was examined. NAC treatment resulted in the reduction of Cd-induced chromosomal DNA fragmentation in agarose gel electrophoresis. Terminal deoxynucleotidyl transferase dUTP nick end-labeling (TUNEL) assay showed that treatment of NAC reduced the Cd-induced apoptosis of germ cells. The administration of NAC showed that the translocation of apoptosis inducing factor (AIF) from mitochondria to nucleus was prevented, which indicated that the mechanism of Cd-induced testicular apoptosis is mediated through the release of AIF in caspase-independent manner. Taken together, the NAC may remove Cd-induced ROS and protect ROS-induced cell apoptosis in rat testis.

• Clinical and Experimental Reproductive Medicine
• /
• 제27권3호
• /
• pp.307-311
• /
• 2000

Objective: To report the successful delivery in a patient of recurrent spontaneous abortion caused by chromosomal abnormality. Material and Method: Case report. Results: Twelve oocytes were obtained by in vitro fertilization. Of eleven oocytes fertilized, two embryos turned out to be normal by using fluorescent in situ hybridization on blastomere biopsy. The patient succeeded in pregnancy and the result of amniocentesis was found to be normal. She delivered the healthy female baby by cesarean section. Conclusions: The successful delivery is possible in recurrent spontaneous abortion related with reciprocal translocation by using preimplantation genetic diagnosis.

• Journal of Genetic Medicine
• /
• 제17권2호
• /
• pp.102-107
• /
• 2020

We report the case of an infant with a 4q35.1 deletion with 10p duplication. This mutation is rarely reported in the literature and has been found to have variable clinical findings, often including developmental delay. In this case, the condition was detected by chromosomal microarray analysis after initial manifestation of a feeding problem and developmental delay. Minor dysmorphic features with abnormal neurological examination led to further evaluation. The father's chromosome complement was 46, XY, t(4;10)(q35;p12.2). Parental balanced translocation can go unrecognized, because affected individuals are often phenotypically healthy until they have fertility issues such as recurrent miscarriages or children with severe congenital disorders. Genetic diagnoses help to establish a clear family genetic background that permits the development of clear treatment strategies. Prenatal counseling can also help to understand the possible risks associated with pregnancy or future child planning.

• 항공우주의학회지
• /
• 제31권3호
• /
• pp.82-83
• /
• 2021

Chronic myeloid leukemia (CML) is myeloproliferative neoplasm associated with a characteristic chromosomal translocation (bcr-abl) called Philadelphia chromosome which plays a key role in the pathogenesis. Approximately 85% of patients with CML are in the chronic phase at the time of diagnosis. During this phase, patients are well tolerated and have few symptoms. But untreated, over the course of several years progresses to an accelerated phase and ultimately to a blast crisis, the terminal phase. CML is largely treated with targeted drug therapy called tyrosine-kinase inhibitors (TKIs) which have led to dramatically improved long-term survival rates since 2001. These drugs became standard treatment of this disease and allow most patients to have much better quality of life when compared to the former chemotherapy drugs and the bone marrow transplantation. Imatinib (Gleevec or Glivec, Norvatis) was the first of these TKIs and found to inhibit the progression of CML in the majority of patients (65%-75%) sufficiently to achieve remission. Since the advent of imatinib, CML has become the first neoplasm in which a medical treatment can give to the patient a normal life expectancy.

• Tuberculosis and Respiratory Diseases
• /
• 제45권5호
• /
• pp.984-991
• /
• 1998

연구배경: 폐암을 포함한 여러 종양에서 3p의 allelic loss가 매우 흔하게 관찰된다는 것은 널리 알려진 사실이다. 따라서 이 구역에 암억제유전자가 존재할 가능성이 높다고 생각되어 과거부터 이에 대한 연구가 활발하게 진행되고 있다. 하지만 현재까지는 몇몇 후보 유전자들이 밝혀져 있을 뿐, 확실한 암억제유전자를 규명해내지는 못하고 있는 실정이다. FHIT(Fragile Histidine Triad) 유전자는 최근 주목을 받고 있는 후보 암억제유전자로서 3p14.2에 위치하고 있으며 식도, 위, 두경부암 등의 여러 종양에서 이 위치의 homozygous deletion이 보고된 바 있다. 서열 분석상 이 유전자는 human genome 중 손상에 가장 취약한 곳중 하나인 FRA3B fragile site와 신세포암에서 잘 발견되는 t(3;8) chromosomal translocation의 breakpoint를 포함하고 있다. 이러한 구조적 특정과 함께 폐암에서 3p의 allelic loss가 특히 높은 빈도로 나타난다는 점에 주목하여, 연자들은 폐암 세포주를 대상으로 FHIT 유전자의 발현 이상을 살펴봄으로써 암억제유전자로서의 가능성을 평가하고자 하였다. 방 법: 총 21개 세포주(비소세포폐암 : 16, 소세포폐암 : 5)를 배양하여 RNA를 분리하였고 reverse transcription을 시행하여 single-strand cDNA를 합성하였다. 이후 FHIT 유전자의 exon 5에서 exon 9에 해당하는 coding region을 PCR로 증폭하였다. 이 PCR product를 ethidium bromide로 염색된 1.5 % agarose gel에서 전기영동시킨 후 band를 관찰하였다. 결 과: 총 21개 폐암 세포주중 12개(57%) 세포주에서 비정상적인 band가 관찰되거나(3개), band가 관찰되지 않았다(9개). 16개의 비소세포폐암 세포주중 7개 (44%)에서 비정상적인 band가 관찰되거나(2개), band가 관찰되지 않았다(5개). 5개의 소세포폐암 세포주에서는 5개(100%) 모두에서 비정상적인 band가 관찰되거나(1개), band가 관찰되지 않았다 (4개). 결 론: 이러한 결과를 살펴볼 때, FHIT 유전자의 발현 이상은 폐암, 특히 소세포폐암에서 높은 빈도로 관찰되었으며, 이는 FHIT 유전자가 폐암 발생에 있어서 중요한 암억제유전자일 것이라는 가설을 뒷받침하는 소견이라 생각된다.

• Clinical and Experimental Pediatrics
• /
• 제50권9호
• /
• pp.875-881
• /
• 2007

목 적 : 염색체의 구조 및 유전을 연구하는 학문인 세포유전학은 임상 진단, 생식 문제, 산전 진단, 종양, 유전자의 다형성 및 유전 상담에 있어 중요한 역할을 하고 있다. 이 연구는 단일 기관에서 시행된 말초혈액을 이용한 세포유전학 검사 결과를 검토하여 주요 염색체 이상의 양상과 빈도를 분석하였다. 방 법 : 1981년 5월부터 2005년 10월까지 25년간 경북대학교병원 소아과 염색체 검사실로 각 임상 진료과에서 염색체 이상이 의심되어 의뢰한 말초혈액 검체 4,856례를 대상으로 하여 염색체 핵형을 분석하였다. 결 과 : 총 4,856례 가운데 4,567례를 분석하였다. 이 중 소아는 3,014례(66.0%), 성인은 1,553례(34.0%)였으며, 검사를 의뢰한 가장 흔한 이유는 소아에서는 성장과 발달 장애, 성인에서는 생식 문제였다. 4,567례 중 염색체 이상은 770례(16.9%)에서 발견되었다. 염색체 이상 중 수적 이상은 558례(12.2%), 구조적 이상은 187례(4.1%)였으며, 취약부위나 염색체 파손과 같은 이상이 25례(0.5%)였다. 수적 이상 중 상염색체 이상은 Down 증후군이 294례(6.4%)로 가장 많았으며, Edwards 증후군 7례(0.2 %), Patau 증후군 4례(0.1%) 순이었다. 성염색체의 이상은 Klinefelter 증후군이 131례(2.9%)로 가장 많았고, Turner 증후군 99례(2.2%), XXX 증후군 8례(0.2%), XYY 증후군 3례(0.1%) 순이었다. 구조적 이상은 전위가 84례(1.8%)로 가장 많았다. 결 론 : 본 연구에서 염색체 이상 핵형의 유형과 그 양상을 파악하였으며, 적극적 세포유전학적 연구로 진료와 유전상담에 적용하여야 할 것이다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제17권10호
• /
• pp.4583-4586
• /
• 2016

Background: Mantle cell lymphoma (MCL) is an aggressive non-Hodgkin's lymphoma, with a pathognomonic chromosomal translocation t (11;14). Prognosis is uniformly dismal but there is a paucity of information on MCL from India. Materials and methods: We retrospectively analysed clinicopathological information on all treated patients with MCL at our centre. STATA 14.0 was used for analysis. Survival was assessed by Kaplan-Meier analysis and the Cox's proportional hazards method. Statistical significance was defined as a P value of < 0.05. Results: Fifty-one patients with MCL were reviewed. The median age at presentation was 57.0 years. Extranodal involvement was seen in 39.0 (74.0%) while bone marrow positivity at presentation was found in 27.0 (54.0%). Initial treatment was chemotherapy with or without rituximab. Patients receiving rituximab-based therapy (n = 24) had 5-year progression-free survival (PFS) of 21.0 (88.0%), compared with 14.0 (61.0%) for those not receiving rituximab (n = 23, P = 0.036). Twenty-three patients were alive with a median follow-up of 20.7 months (range 2.5-89.2). PFS at 1 and 2 years was 51.0% and 27.0%, and overall survival (OS) 78.0% and 72.0%, respectively. Use of more than 2.0 lines of therapy, use of bendamustine-rituximab, and high TLC (>10,000.0/cu.mm) significantly affected PFS. Conclusions: In our experience, MCL patients from north India have an early age at presentation. When treated with regimens including rituximab results in an improved response rate and PFS. This study provided comprehensive insights into the treatment of MCL in a developing country.

• 대한임상검사과학회지
• /
• 제39권3호
• /
• pp.151-155
• /
• 2007

Diagnosis and prevention of cytogenetics diseases are one of the most important parts in prenatal care. For that reason, it is necessary to examine birth defects. However, there is no reliable statistical data about birth defects in our country. In this study, the ratio of birth defects were determined by cytogenetics analysis and amniocentesis, in addition, the usefulness of amniocentesis was analyzed. The screening test and the triple marker test were conducted for 3,325 pregnant women of between 15 and 22 weeks gestation. Amniocentesis was performed for 170 pregnant women who were positive in the two tests, 184 women of advanced maternal age and 48 women with family history of chromosome aberrations. Among 419 women, 8 pregnant women who were positive in the triple marker test, 1 woman who close to the cut-off value in the triple marker test, 2 women with advanced maternal age and 1 woman who has history of chromosome aberration pregnance that was positive in cytogenetics analysis. The overall incidence of chromosomal aberration was 12 cases including 7 cases of Down's syndrome, 1 case of Patau syndrome, 1 case of Klinefelter syndrome, 1 case of Edward syndrome, 1 case of Robertsonian translocation and 1 case of XYY syndrome. These results show that amniocentesis for pregnant women who need chromosome test in prenatal cytogenetics analysis is very useful.

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권8호
• /
• pp.3541-3546
• /
• 2014

TEL-AML1 fusion oncogene (t 12; 21) is the most common chromosomal abnormality in childhood acute lymphoblastic leukemia (ALL). This translocation is associated with a good prognosis and rarely shows chemotherapeutic resistance to 3-drug based remission induction phase of treatment as well as overall treatment. Thus, the higher the frequency of this fusion oncogene, the easier to manage childhood ALL in a given region with less intensive chemotherapy. Although global frequency of TEL-AML1 has been reported to be 20-30%, a very low frequency has been found in some geographical regions, including one study from Lahore, Punjab, Pakistan and others from India. The objective of present study was to investigate if this low frequency of TEL-AML1 in pediatric ALL is only in Lahore region or similar situation exists at other representative oncology centers of Pakistan. A total of 167 pediatric ALL patients were recruited from major pediatric oncology centers situated in Lahore, Faisalabad, Peshawar and Islamabad. Patients were tested for TEL-AML1 using nested reverse transcription polymerase chain reaction (RT-PCR). Only 17 out of 167 (10.2%) patients were found to be TEL-AML1 positive. TEL-AML1+ALL patients had favorable prognosis, most of them (82.4%, 14/17) showing early remission and good overall survival. Thus, our findings indicate an overall low frequency of TEL-AML1 in Pakistan pediatric ALL patients, in accordance with lower representation of this prognostically important genetic abnormality in other less developed countries, specifically in south Asia, thus associating it with poor living standards in these ethnic groups. It also indicates ethnic and geographical differences in the distribution of this prognostically important genetic abnormality among childhood ALL patients, which may have a significant bearing on ALL management strategies in different parts of the world.

• Genomics & Informatics
• /
• 제17권3호
• /
• pp.26.1-26.12
• /
• 2019

Identification of fusion gene is of prominent importance in cancer research field because of their potential as carcinogenic drivers. RNA sequencing (RNA-Seq) data have been the most useful source for identification of fusion transcripts. Although a number of algorithms have been developed thus far, most programs produce too many false-positives, thus making experimental confirmation almost impossible. We still lack a reliable program that achieves high precision with reasonable recall rate. Here, we present FusionScan, a highly optimized tool for predicting fusion transcripts from RNA-Seq data. We specifically search for split reads composed of intact exons at the fusion boundaries. Using 269 known fusion cases as the reference, we have implemented various mapping and filtering strategies to remove false-positives without discarding genuine fusions. In the performance test using three cell line datasets with validated fusion cases (NCI-H660, K562, and MCF-7), FusionScan outperformed other existing programs by a considerable margin, achieving the precision and recall rates of 60% and 79%, respectively. Simulation test also demonstrated that FusionScan recovered most of true positives without producing an overwhelming number of false-positives regardless of sequencing depth and read length. The computation time was comparable to other leading tools. We also provide several curative means to help users investigate the details of fusion candidates easily. We believe that FusionScan would be a reliable, efficient and convenient program for detecting fusion transcripts that meet the requirements in the clinical and experimental community. FusionScan is freely available at http://fusionscan.ewha.ac.kr/.